Hookipa Pharma Stock Scheduled to Reverse Split on Wednesday, July 10th (NASDAQ:HOOK)

Hookipa Pharma Inc (NASDAQ:HOOK) shares are going to reverse split on the morning of Wednesday, July 10th. The 1-10 reverse split was announced on Wednesday, July 10th. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, July 10th.

Hookipa Pharma Stock Down 9.3 %

NASDAQ:HOOK traded down $0.05 during mid-day trading on Monday, hitting $0.51. 1,566,233 shares of the company traded hands, compared to its average volume of 717,963. The stock’s fifty day moving average price is $0.76 and its 200-day moving average price is $0.75. Hookipa Pharma has a one year low of $0.41 and a one year high of $1.13. The firm has a market cap of $50.69 million, a price-to-earnings ratio of -1.02 and a beta of 0.81.

Hookipa Pharma (NASDAQ:HOOK) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.24. Hookipa Pharma had a negative return on equity of 33.33% and a negative net margin of 88.73%. The company had revenue of $36.60 million during the quarter, compared to the consensus estimate of $3.20 million. During the same period in the previous year, the company posted ($0.27) EPS. Equities analysts predict that Hookipa Pharma will post -0.46 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on HOOK shares. HC Wainwright upped their target price on shares of Hookipa Pharma from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Wednesday, June 5th. Royal Bank of Canada restated an “outperform” rating and issued a $5.00 price objective on shares of Hookipa Pharma in a research report on Tuesday, May 21st.

Institutional Trading of Hookipa Pharma

An institutional investor recently raised its position in Hookipa Pharma stock. Acadian Asset Management LLC grew its stake in Hookipa Pharma Inc (NASDAQ:HOOK) by 85.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 882,262 shares of the company’s stock after purchasing an additional 407,532 shares during the period. Acadian Asset Management LLC owned approximately 0.89% of Hookipa Pharma worth $627,000 at the end of the most recent reporting period. 63.88% of the stock is owned by institutional investors.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.